Comparative Pharmacology
Head-to-head clinical analysis: LYBALVI versus SAPHRIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LYBALVI versus SAPHRIS.
LYBALVI vs SAPHRIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LYBALVI is a combination of olanzapine and samidorphan. Olanzapine is an atypical antipsychotic with high affinity for serotonin 5-HT2A and 5-HT2C, dopamine D1-D4, histamine H1, and alpha1-adrenergic receptors. Samidorphan is an opioid receptor antagonist with high affinity for mu-opioid receptors, hypothesized to reduce olanzapine-associated weight gain by blocking opioid receptors in the central nervous system.
Asenapine is an atypical antipsychotic with high affinity for serotonin 5-HT2A, 5-HT2C, 5-HT6, and 5-HT7 receptors; dopamine D2, D3, and D4 receptors; and alpha2-adrenergic receptors. It also has moderate affinity for histamine H1 and alpha1-adrenergic receptors, and low affinity for muscarinic M1 receptors.
Olanzapine 10 mg / samidorphan 10 mg orally once daily.
5 mg sublingually twice daily, may increase to 10 mg twice daily based on tolerability and efficacy.
None Documented
None Documented
Terminal half-life ~20-30 hours; supports once-daily dosing.
Terminal elimination half-life is 30-40 hours, supporting once-daily dosing.
Renal: ~50% as unchanged drug and metabolites; Fecal: ~40%; Biliary: minor.
After oral administration, approximately 50% of the dose is excreted in urine (mostly as metabolites, <1% unchanged) and 40% in feces (mostly as metabolites).
Category C
Category C
Atypical Antipsychotic
Atypical Antipsychotic